Physician profile
William P Barrett
NPI 1528001682
$7,679,646.29
in general payments reported to CMS, 2019-2025
11 companies · $814K in 2025
The $814K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2.1M · 2020: $1.4M · 2021: $996K · 2022: $928K · 2023: $841K · 2024: $690K · 2025: $814K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $2.2M · Consulting Fee: $143K · Travel and Lodging: $18K · Food and Beverage: $2,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $2,181,437.88 |
| Consulting Fee | $142,557.54 |
| Travel and Lodging | $18,303.64 |
| Food and Beverage | $2,867.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $6,786,346.85 | 2019-2025 | Pinnacle, Attune, Velys |
| Medical Device Business Services, INC. | $849,020.26 | 2019-2024 | Velys, Na, Attune |
| Ethicon INC. | $11,565.00 | 2019-2021 | |
| Ethicon Endo-Surgery INC. | $11,560.00 | 2020 | |
| Depuy Synthes Sales INC. | $9,510.71 | 2019-2024 | Velys, Attune, Actis |
| Pacira Pharmaceuticals Incorporated | $7,700.36 | 2020-2021 | |
| Ethicon US, LLC | $3,334.50 | 2021-2024 | Stratafix, Dermabond |
| Kci USA, INC. | $555.34 | 2019 | |
| Medtronic, INC. | $21.57 | 2022 | |
| Orthofix Medical, INC. | $15.87 | 2022 | |
| Johnson & Johnson Health Care Systems INC. | $15.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.